Studies have found that if the LDL cholesterol is reduced to less than 70 mg/dL and preferably less than 55 mg/dL, the size of the plaques can get smaller.19-Jul-2021
https://www.uptodate.com/contents/high-cholesterol-and-lipid-treatment-options-beyond-the-basics
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
Dhrubajyoti Bandyopadhyay,corresponding author 1 Arshna Qureshi, 2 Sudeshna Ghosh, 3 Kumar Ashish, 4 Lyndsey R. Heise, 5 Adrija Hajra, 6 and Raktim K. Ghosh 7
J Lipids. 2018; 2018: 8598054. Published online 2018 Apr 23. doi: 10.1155/2018/8598054
PMCID: PMC5937425PMID: 29850255
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937425/
PCSK9 Therapies
Inclisiran from Novartis
Inclisiran - It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
John LaMattinaContributor
I cover news on drugs and R&D in the pharma industry
Jan 3, 2022,
https://www.forbes.com/sites/johnlamattina/2022/01/03/it-was-to-be-the-cholesterol-drug-for-the-masses-novartis-changed-that/
Two PCSK9 antibodies were approved by the FDA in 2015: Praluent (Sanofi/Regeneron) and Repatha (Amgen). Unfortunately, the list prices of these much anticipated drugs were initially set at a jaw dropping $14,000/year/patient.
No comments:
Post a Comment